Volitionrx LTD 8-K filings

VolitionRx Limited announced the issuance of shares to Lind Global Asset Management XII LLC to satisfy payment and conversion obligations related to senior secured convertible promissory notes.

VolitionRx Limited filed an 8-K detailing the reduction of its authorized common stock and the approval of its 2026 Stock Incentive Plan following its annual stockholder meeting.

VolitionRx Limited announced the issuance of common stock to Lind Global Asset Management XII LLC to satisfy debt obligations under a convertible promissory note.

VolitionRx Limited has entered into a waiver agreement with Lind Global Asset Management XII LLC following a breach of its market capitalization covenant.

VolitionRx Limited announced that director Mickie Henshall will not stand for re-election at the 2026 Annual Meeting.

VolitionRx Limited reported a significant increase in first-quarter revenue to $1.0 million and a 3% reduction in operating loss, alongside progress in its diagnostic test development and commercialization efforts.

VolitionRx Limited has implemented a one-for-twenty reverse stock split of its common stock, effective April 28, 2026.

VolitionRx Limited announced its compliance plan to regain NYSE American listing standards has been accepted, granting it until August 6, 2027, to meet requirements.

VolitionRx Limited will implement a one-for-twenty reverse stock split effective April 28, 2026, to comply with financing agreement terms.

VolitionRx Limited stockholders approved the issuance of additional shares to Lind Global Asset Management XII LLC and a potential reverse stock split at a special meeting.

VolitionRx Limited announced its full fiscal year 2025 financial results, reporting significant revenue growth and key advancements in its Nu.Q Cancer and Nu.Q NETs assays.

VolitionRx Limited received a notice from NYSE American for non-compliance with continued listing standards due to insufficient stockholders' equity and sustained losses.

VolitionRx Limited has secured an additional $2.0 million in gross funding from Lind Global Asset Management XII LLC through a senior secured convertible promissory note and common stock purchase warrants.

VolitionRx Limited's majority-owned subsidiary, Volition Veterinary, is eliminating its Chief Executive Officer position as part of cost-realignment efforts, effective January 31, 2026.

VolitionRx Limited announced its third quarter 2025 financial results, reporting a 32% revenue increase and securing two significant human diagnostics agreements.

VolitionRx Limited amended its underwriting agreement and Newbridge Securities Corporation exercised its over-allotment option, generating $582,426 in net proceeds for the company.

VolitionRx Limited filed an amended 8-K to correct typographical errors and detail the modification and partial exercise of an over-allotment option in its recent public offering.

VolitionRx Limited amended its underwriting agreement to allow for partial exercise of its over-allotment option, leading to the sale of additional shares and warrants.

VolitionRx Limited announced the pricing of an underwritten public offering of 11.55 million shares of common stock and accompanying warrants, expecting to raise approximately $6.0 million in gross proceeds.

VolitionRx Limited reported improved Q2 2025 financial results and anticipates signing its first human diagnostics licensing agreement this quarter.

VolitionRx Limited announced a registered direct offering raising $1.21 million through the sale of common stock and warrants to existing stockholders and insiders.

VolitionRx Limited stockholders approved an increase in authorized common stock from 175 million to 325 million shares, alongside the re-election of directors and ratification of auditors, at their Annual Meeting on June 18, 2025.

VolitionRx Limited reports a 44% increase in revenue for Q1 2025 and announces first revenue from its CE-marked Nu.Q NETs automated product in Europe.

VolitionRx Limited has entered into a sales agreement with JonesTrading Institutional Services LLC to offer and sell up to $7.5 million of its common stock through an 'at the market' offering.

VolitionRx Limited has filed a new registration statement to register shares issuable upon the exercise of previously issued warrants.

VolitionRx reports increased revenue for fiscal year 2024, driven by Nu.Q Vet Cancer Test sales, and outlines its strategy to secure licensing deals in the human diagnostics market.

VolitionRx Limited announces a registered direct offering to raise up to $2.3 million, with potential additional proceeds from warrant exercises.

VolitionRx Limited has successfully raised approximately $1.9 million through a direct offering of common stock and warrants, with the potential for an additional $2.7 million if warrants are fully exercised.

VolitionRx announced a significant increase in revenue and sales of its Nu.Q Vet Cancer Tests, alongside advancements in human clinical programs and strategic partnerships.

VolitionRx Limited has appointed Timothy Still as the new non-executive Chairman of its Board of Directors, effective November 6, 2024, while also expanding the board to eight members.